Biodextris
525 Cartier Boulevard West
Laval
Quebec
H7V 3S8
Canada
Tel: 450-965-8213 ext: 100
Website: http://biodextris.com/
Email: info@biodextris.com
About Biodextris
Biodextris is comprised of experienced product development scientist located in Laval (Montreal), Quebec. The group has worked together since 2002, as part of ID Biomedical and later GSK-Vaccines. We have developed numerous products for all phases of clinical development for programs conducted in the US, Canada and Europe.Our history leaves us with the know-how for high quality, robust, commercial product development combined with flexibility and the sense of urgency inherent in smaller organizations.
We look forward to sharing this expertise with you.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO & President: Joseph Zimmermann
Director, Analytical Services: Christine Jacques
Director, Process Services: Paul Rice
SERVICES:
Please click here for Biodextris' services.
2 articles about Biodextris
-
Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine
3/9/2021
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides
-
Accinov And BiodextrisTeam Up To Provide A Unique Contract Development And Manufacturing Service Package
11/29/2016